GILD double bottom on daily, Broke Down Trend, New HEPB Trials $
Gild on 1/12 announced a partnership for a phase 2 trial on a new HEP B cure. It also got an upgrade on Jan 4th and it's covid treatment usage is going up due to rising covid numbers. Waiting for trigger of close above .618 fib for a weekly swing on this ticker. Overall Gild looks promising long term.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.